Results By discharge or Day 90, 78.2% of the cohort expired. The most common pre-existing conditions were hypertension, (63.5%), diabetes (59.2%) and obesity (50.4%). Age correlated with death. Comorbidities and clinical status on presentation were not predictive of outcome. Admission markers of inflammation were universally elevated (>96%). The cohort’s weight range was nearly 7-fold. Causal modeling establishes that weight-adjusted HCQ and AZM therapy improves survival by over 100%. QTc prolongation did not correlate with cumulative HCQ dose or HCQ serum levels.
https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
Lets not forget there have also been studies showing that if you administer this combo in the first 5 days you also see improved results.
https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1
Lets not forget there have also been studies showing that if you administer this combo in the first 5 days you also see improved results.